Press releases

SeraNovo Welcomes Distinguished Scientific Advisory Board

SeraNovo Welcomes Distinguished Scientific Advisory Board

Delve into the insights of SeraNovo's Scientific Advisory Board.

Read more
 SeraNovo And AstraZeneca To Collaborate On Research Projects

SeraNovo And AstraZeneca To Collaborate On Research Projects

SeraNovo is pleased to announce the closing of a multicompound deal with AstraZeneca (Cambridge, United Kingdom).

Read more
SeraNovo and Ildong Pharmaceutical to collaborate on research projects

SeraNovo and Ildong Pharmaceutical to collaborate on research projects

SeraNovo Enters into a multi-compound deal with Ildong Pharmaceutical.

Read more
SeraNovo and Graviton deepen collaboration

SeraNovo and Graviton deepen collaboration

SeraNovo and Graviton deepen collaboration and enter into a second license agreement to develop formulations for Graviton's ROCK-2 inhibitors

Read more
Pharmaceutical product based on SeraNovo’s eutectic formulation technology enters phase I clinical study

Pharmaceutical product based on SeraNovo’s eutectic formulation technology enters phase I clinical study

SeraNovo is proud to announce that in December 2021, Carna Biosciences initiated a clinical study with a drug product based on a joint development program

Read more
SeraNovo Enters into License Agreement with Équilibre BioPharmaceuticals

SeraNovo Enters into License Agreement with Équilibre BioPharmaceuticals

SeraNovo Enters into a License Agreement with Équilibre BioPharmaceuticals

Read more